November 1, 2025 • 6 mins
# Ozempic's Expanding Impact: Beyond Weight Loss to Heart Health and Aging
In this eye-opening episode of Navigating Ozempic, we explore groundbreaking developments from the past three days that reveal how this popular medication is revolutionizing healthcare far beyond its weight-loss reputation.
Discover the surprising findings from University College London's new research published in The Lancet showing Ozempic significantly reduces heart attack and stroke risk—even in patients who lose minimal weight. We dive into fascinating evidence suggesting semaglutide may actually reverse biological aging by up to three years, according to new clinical trial data.
Our episode also examines how GLP-1 medications like Ozempic are reshaping public health statistics, with the US adult obesity rate dropping from 40% to 37% as usage doubles among American adults. Plus, get an exclusive look at Ozempic's global expansion into India, including pricing comparisons and accessibility insights from leading endocrinologists.
Whether you're considering GLP-1 medications, already taking them, or simply interested in the future of metabolic health, this episode provides crucial context on how Ozempic is transforming medicine, economics, and our understanding of chronic disease management.
#Ozempic #WeightLossInjections #HeartHealth #AntiAging #GLP1 #OzempicResearch #MetabolicHealth #DiabetesTreatment
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
In this eye-opening episode of Navigating Ozempic, we explore groundbreaking developments from the past three days that reveal how this popular medication is revolutionizing healthcare far beyond its weight-loss reputation.
Discover the surprising findings from University College London's new research published in The Lancet showing Ozempic significantly reduces heart attack and stroke risk—even in patients who lose minimal weight. We dive into fascinating evidence suggesting semaglutide may actually reverse biological aging by up to three years, according to new clinical trial data.
Our episode also examines how GLP-1 medications like Ozempic are reshaping public health statistics, with the US adult obesity rate dropping from 40% to 37% as usage doubles among American adults. Plus, get an exclusive look at Ozempic's global expansion into India, including pricing comparisons and accessibility insights from leading endocrinologists.
Whether you're considering GLP-1 medications, already taking them, or simply interested in the future of metabolic health, this episode provides crucial context on how Ozempic is transforming medicine, economics, and our understanding of chronic disease management.
#Ozempic #WeightLossInjections #HeartHealth #AntiAging #GLP1 #OzempicResearch #MetabolicHealth #DiabetesTreatment
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome back to Navigating Ozepic, your destination for the latest
insights into one of the world's most talked about medicines. Today,
we unpack the newest developments from the last three days,
exploring how ozempic continues to shape both wellness routines and
medical treatments, how its redefining costs and access, and how
its benefits reach far beyond the scale. A newly published
(00:22):
study from University College London just shook up our understanding
of ozempic's heart health effects. According to research featured in
The Lancet and covered by outlets like Science Daily, summerglue tide,
known to most as ozempic or wedov, significantly reduces the
risk of heart attacks and strokes, even if the person
taking it loses little to no weight. The study followed
(00:44):
more than seventeen thousand adults with cardiovascular disease. Whether participants
shed pounds or not, their risk of major cardiac events
dropped by about twenty percent. Waste size did correlate with
about one third of the heart protection, underscoring the connect
between belly fat and heart disease. But the real story
is that ozempic's cardiovascular benefits are not limited to those
(01:07):
seeing dramatic changes on the scale. This marks a turning point.
Ozempic is being recognized for direct heart protection, not just
as a tool for weight loss. On a surprising frontier,
research released this week and highlighted by Pharmaceutical Executive Daily
and Applied Clinical Trials suggests ozempic may potentially reverse parts
(01:28):
of biological aging. An investigation by True Diagnostic included a
thirty two week placebo controlled trial where ozepic users reduced
their biological age by just over three years as measured
by epigenetic aging clocks. This study, conducted in individuals living
with HIV, hints that ozempic's molecular impacts may extend well
(01:50):
beyond metabolic and cardiovascular effects. Scientists are clear more research
is needed, especially outside the HIV population, but this result
opens fresh doors for gl P DASH one drugs in
precision medicine. Turning to the big picture, rapid adoption of
ozempic and similar GLP DASH one drugs has started to
(02:10):
leave a mark on America's public health landscape. Dellip, whose
new poll was covered by CBS News and Health Line
this week, reported that the national adult obesity rate in
the United States has declined, dropping from a record high
of nearly forty percent in twenty twenty two to thirty
seven percent in twenty twenty five. That translates to an
estimated seven and a half million fewer obese adults compared
(02:33):
to three years ago. The drop is strongly linked to
the surge in weight loss injections. Usage of GLP one
drugs for weight loss jumped from just under six percent
in early twenty twenty four to more than twelve percent
by now. Women are leading this trend, with about fifteen
percent reporting use of weight management injectables compared to just
(02:54):
under ten percent of men. Interestingly, many of these new
users are between the ages of forty and sixty four,
a demographic carrying higher rates of obesity and who, according
to the poll, are more aware and likely to enroll
in GLP one regiments. However, there is a caveat the
same survey detected a rise in diagnosed diabetes rates, which
(03:16):
have now hit record highs. Experts like Kristen Kirkpatrick, a
registered dietitian at Cleveland Clinic, note that while the obesity
drop reflects direct impacts of ozepic and similar drugs, increased
diabetes prevalence seems to mirror broader ongoing metabolic challenges. The
reduction in obesity, supported by real world data and in
(03:36):
clinics across the country is being hailed as a meaningful
public health victory, and the visibility of these drugs has sought,
with national awareness among adults rising from eighty percent to
nearly ninety percent in just the last year across the globe.
In India, ozepic mania is echoing in both diabetes management
and weight loss clinics, as covered recently by the Times
(03:57):
of India. Though the official launch of those is slated
for December, anticipation is intense and pick pricing is already
being debated as patients compare options of ozepic, wagov and Manjaro.
These injections are seen not just as medical treatments, but
as lifestyle statements. Doctor Rajieve Coovil, a leading diebiologist and
(04:19):
weight loss expert, explains that while US users can pay
close to one thousand dollars a month without strong insurance,
Indian patients will face a premium but more accessible price
point about ten thousand Indian rupeas or roughly one hundred
and twenty dollars per month. Weigovy and Munjaro, depending on dose,
are priced higher, but remain within reach for those committed
(04:40):
to metabolic health. Doctor Munjanov Malagai, an endochronology director in Bengaloru,
points out that while these medicines are not cheap, their
costs in India are far lower than in the US.
Direct to consumer programs in America can reduce monthly self
paid to about five hundred dollars, underscoring the fierce competition
and demand pricing. Dynamic reflects ozempic's role not just as
(05:02):
a life saving medication against diabetes, but as a transformative
lifestyle therapy, shaping how people perceive their health, control appetite,
and even navigate social self image. Medical professionals continue to
urge caution, reminding listeners that ozempic is neither a magic
shot nor a replacement for healthy living. The science is robust,
(05:23):
but its benefits, whether in reducing cardiovascular risk, lowering biological age,
or driving weight loss, depend on continued use, medical supervision
and lifestyle support. Affordability, whether measured in dollars or rupees,
remains a critical factor in wider access, as only those
able and willing to sustain therapy will see long term
(05:44):
results for listeners curious about Ozepic versus newer alternatives like
Munjaro or Wagovi. Leading Indian clinicians weigh in on which
medication suits which patient best. Ozempic and Munjaro are primarily
diabetes treatments with weight loss side effects, whereas Weigovie is
designed specifically for weight management and offers additional benefits in
(06:05):
obesity link health risks. The three drugs differ in MECCA
Welcome back to Navigating Ozepic, your destination for the latest
insights into one of the world's most talked about medicines. Today,
we unpack the newest developments from the last three days,
exploring how ozempic continues to shape both wellness routines and
medical treatments, how its redefining costs and access, and how
its benefits reach far beyond the scale. A newly published
(00:22):
study from University College London just shook up our understanding
of ozempic's heart health effects. According to research featured in
The Lancet and covered by outlets like Science Daily, summerglue tide,
known to most as ozempic or wedov, significantly reduces the
risk of heart attacks and strokes, even if the person
taking it loses little to no weight. The study followed
(00:44):
more than seventeen thousand adults with cardiovascular disease. Whether participants
shed pounds or not, their risk of major cardiac events
dropped by about twenty percent. Waste size did correlate with
about one third of the heart protection, underscoring the connect
between belly fat and heart disease. But the real story
is that ozempic's cardiovascular benefits are not limited to those
(01:07):
seeing dramatic changes on the scale. This marks a turning point.
Ozempic is being recognized for direct heart protection, not just
as a tool for weight loss. On a surprising frontier,
research released this week and highlighted by Pharmaceutical Executive Daily
and Applied Clinical Trials suggests ozempic may potentially reverse parts
(01:28):
of biological aging. An investigation by True Diagnostic included a
thirty two week placebo controlled trial where ozepic users reduced
their biological age by just over three years as measured
by epigenetic aging clocks. This study, conducted in individuals living
with HIV, hints that ozempic's molecular impacts may extend well
(01:50):
beyond metabolic and cardiovascular effects. Scientists are clear more research
is needed, especially outside the HIV population, but this result
opens fresh doors for gl P DASH one drugs in
precision medicine. Turning to the big picture, rapid adoption of
ozempic and similar GLP DASH one drugs has started to
(02:10):
leave a mark on America's public health landscape. Dellip, whose
new poll was covered by CBS News and Health Line
this week, reported that the national adult obesity rate in
the United States has declined, dropping from a record high
of nearly forty percent in twenty twenty two to thirty
seven percent in twenty twenty five. That translates to an
estimated seven and a half million fewer obese adults compared
(02:33):
to three years ago. The drop is strongly linked to
the surge in weight loss injections. Usage of GLP one
drugs for weight loss jumped from just under six percent
in early twenty twenty four to more than twelve percent
by now. Women are leading this trend, with about fifteen
percent reporting use of weight management injectables compared to just
(02:54):
under ten percent of men. Interestingly, many of these new
users are between the ages of forty and sixty four,
a demographic carrying higher rates of obesity and who, according
to the poll, are more aware and likely to enroll
in GLP one regiments. However, there is a caveat the
same survey detected a rise in diagnosed diabetes rates, which
(03:16):
have now hit record highs. Experts like Kristen Kirkpatrick, a
registered dietitian at Cleveland Clinic, note that while the obesity
drop reflects direct impacts of ozepic and similar drugs, increased
diabetes prevalence seems to mirror broader ongoing metabolic challenges. The
reduction in obesity, supported by real world data and in
(03:36):
clinics across the country is being hailed as a meaningful
public health victory, and the visibility of these drugs has sought,
with national awareness among adults rising from eighty percent to
nearly ninety percent in just the last year across the globe.
In India, ozepic mania is echoing in both diabetes management
and weight loss clinics, as covered recently by the Times
(03:57):
of India. Though the official launch of those is slated
for December, anticipation is intense and pick pricing is already
being debated as patients compare options of ozepic, wagov and Manjaro.
These injections are seen not just as medical treatments, but
as lifestyle statements. Doctor Rajieve Coovil, a leading diebiologist and
(04:19):
weight loss expert, explains that while US users can pay
close to one thousand dollars a month without strong insurance,
Indian patients will face a premium but more accessible price
point about ten thousand Indian rupeas or roughly one hundred
and twenty dollars per month. Weigovy and Munjaro, depending on dose,
are priced higher, but remain within reach for those committed
(04:40):
to metabolic health. Doctor Munjanov Malagai, an endochronology director in Bengaloru,
points out that while these medicines are not cheap, their
costs in India are far lower than in the US.
Direct to consumer programs in America can reduce monthly self
paid to about five hundred dollars, underscoring the fierce competition
and demand pricing. Dynamic reflects ozempic's role not just as
(05:02):
a life saving medication against diabetes, but as a transformative
lifestyle therapy, shaping how people perceive their health, control appetite,
and even navigate social self image. Medical professionals continue to
urge caution, reminding listeners that ozempic is neither a magic
shot nor a replacement for healthy living. The science is robust,
(05:23):
but its benefits, whether in reducing cardiovascular risk, lowering biological age,
or driving weight loss, depend on continued use, medical supervision
and lifestyle support. Affordability, whether measured in dollars or rupees,
remains a critical factor in wider access, as only those
able and willing to sustain therapy will see long term
(05:44):
results for listeners curious about Ozepic versus newer alternatives like
Munjaro or Wagovi. Leading Indian clinicians weigh in on which
medication suits which patient best. Ozempic and Munjaro are primarily
diabetes treatments with weight loss side effects, whereas Weigovie is
designed specifically for weight management and offers additional benefits in
(06:05):
obesity link health risks. The three drugs differ in MECCA
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies!
The Breakfast Club
The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious, And Charlamagne Tha God!